Phase II Study of Dasatinib in Patients With Advanced Non–Small-Cell Lung Cancer

PURPOSE: Src family kinases (SFKs) promote cancer progression and are commonly expressed in non–small-cell lung cancer (NSCLC), but the clinical effects of SFK inhibition in NSCLC are unknown. We conducted a phase II trial of the SFK inhibitor dasatinib for advanced NSCLC. We tested the hypotheses t...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Johnson, Faye M., Bekele, B. Nebiyou, Feng, Lei, Wistuba, Ignacio, Tang, Xi Ming, Tran, Hai T., Erasmus, Jeremy J., Hwang, Li-Ling, Takebe, Naoko, Blumenschein, George R., Lippman, Scott M., Stewart, David J.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2010
Assuntos:
Original Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2974341/
https://ncbi.nlm.nih.gov/pubmed/20855820
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2010.30.5474
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados